Patient-derived organoid (PDO) gastrointestinal biobank

Patient-derived organoids (PDOs) are novel in vitro 3D cell models that preserve original tissue physiology and molecular pathology, thus representing a clinically relevant alternative to traditional 2D cell lines and an effective tool to refine and reduce animal models.

In this free download, explore Merck’s comprehensive biobank of highly characterized tissue-derived human gastrointestinal organoids from normal and diseased patients. The intestinal organoid biobank contains over 50 highly characterized intestinal organoids from both normal and diseased patients derived from multiple regions of the digestive systems including small intestine (duodenum, ileum), stomach, rectum and colon.

MilliporeSigma is the Life Science business of Merck KGaA, Darmstadt, Germany in the USA and Canada.

3dGRO™ organoids were derived utilizing HUB Organoid Technology.